Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Co. is developing antisense oligonucleotides to selectively restore protein levels. Co.'s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Co.'s second product candidate, STK-002, is in development for treatment of Autosomal Dominant Optic Atrophy. We show 20 historical shares outstanding datapoints in our STOK shares outstanding history coverage, used to compute STOK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing STOK market cap history over the course of time is important for investors
interested in comparing STOK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of STOK versus a peer is one thing; comparing
STOK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like STOK can fluctuate over the course of history.
With this page we aim to empower investors researching STOK by allowing them to research the STOK market cap history. |
Free STOK Email Alerts:
Video: The Importance of Market Cap
